Opportunity Information: Apply for PA 13 077
Apply for PA 13 077
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Behavioral Integrative Treatment Development Program (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213 Research and Training in Complementary and Integrative Health 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Feb 14, 2013 and posted on Jan 9, 2013.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Small businesses For profit organizations other than small businesses Private institutions of higher education Public and State controlled institutions of higher education County governments City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Behavioral Integrative Treatment Development Program (R01), Funding Opportunity Number PA-13-077, is a National Institutes of Health (NIH) discretionary grant program designed to move behavioral intervention research beyond early development and into more rigorous testing and refinement. The central aim is to support R01 projects that develop and evaluate behavioral and integrative treatment approaches for drug abuse and addiction, with an emphasis on establishing whether interventions work (efficacy), understanding how and why they work (mechanisms of behavior change), and determining the best way to deliver them (dose, combinations, and sequencing). A major throughline in this announcement is optimization: it is not only about creating new interventions, but also about improving existing approaches by identifying the most effective components, the right intensity or "dose," and how to combine behavioral strategies with medications in ways that are practical and produce better outcomes.
The scope of research encouraged under this FOA is broad, but it centers on six major areas. First, it prioritizes drug abuse treatment interventions, including integrated behavioral and pharmacological approaches, that can be applied across diverse real-world settings and that address patients with comorbidities (for example, co-occurring mental health conditions or other medical problems). Second, it promotes the development and testing of drug abuse treatment and adherence interventions that can be used in primary care, reflecting the increasing role of general medical settings in identifying and managing substance use disorders. Third, it highlights technology-enhanced interventions, such as those using digital tools to strengthen treatment effects, expand reach, reduce burden on clinics, and improve the likelihood that an intervention can be implemented consistently outside of research settings. Fourth, it explicitly includes interventions aimed at preventing HIV acquisition or transmission among individuals who are in drug abuse treatment, recognizing the overlap between substance use, risk behavior, and HIV outcomes. Fifth, it supports interventions that improve adherence, both to drug abuse treatment itself and to HIV and addiction medications, since adherence is often the practical barrier between an evidence-based treatment and real benefit. Sixth, it includes behavioral interventions relevant to chronic pain treatment, which intersects with addiction risk and medication use and has become a significant public health concern.
Methodologically, the FOA is especially interested in later-stage intervention research, including but not limited to Stage II and Stage III efficacy research. In practical terms, that means NIH is looking for studies that go beyond initial feasibility and pilot work and instead test interventions with stronger designs, clearer outcome measures, and more robust clinical trial methods when appropriate. Supported work can include clinical trials that establish efficacy, studies that probe mechanisms of behavior change (for example, identifying which cognitive, social, or environmental processes mediate outcomes), dose-response research to determine the intensity or frequency needed for benefit, and studies that test whether certain sequences or combinations of behavioral and medication treatments outperform others. The announcement also encourages research on integrated care models, sequential strategies (for instance, starting with one approach and stepping up to another), and combined interventions that aim to improve both substance use outcomes and related health risks.
In terms of administrative details, this is an R01 grant mechanism, meaning it is intended for substantial, hypothesis-driven research projects with enough scope to conduct rigorous intervention testing and refinement. The opportunity was posted January 9, 2013, created February 14, 2013, and had an original and final closing date of January 7, 2016, with an archive date of February 7, 2016. While it is archived now, the description captures NIH priorities at the time around behavioral treatment development, integration with pharmacotherapy, technology-supported delivery, and the intersections of addiction with HIV and chronic pain.
Eligibility is broad and includes many types of domestic and international applicants. Eligible organizations include state, county, city or township governments; special district governments; public housing and Indian housing authorities; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (including small businesses and other for-profits); independent school districts; and Native American tribal governments and organizations (both federally recognized and other than federally recognized). The eligibility language also explicitly includes a wide range of mission-driven and underserved-serving institutions and entities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and federal government agencies. Foreign organizations and foreign institutions are eligible, and non-U.S. components of U.S. organizations may apply; foreign components are allowed as defined by the NIH Grants Policy Statement. The announcement indicates there is no cost sharing or matching requirement.
For reference and applicant support, NIH provided an official announcement link through the NIH grants guide (http://grants.nih.gov/grants/guide/pa-files/PA-13-077.html). Assistance with technical access or linking issues was directed to the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs): Behavioral Integrative Treatment Development Program (R01) - PA-13-077
1) What is the Behavioral Integrative Treatment Development Program (R01) (PA-13-077)?
It is an NIH discretionary grant opportunity that uses the R01 mechanism to support projects that develop, evaluate, and refine behavioral and integrative treatment approaches for drug abuse and addiction. A key emphasis is moving beyond early intervention development into more rigorous testing, including efficacy evaluation, studying mechanisms of behavior change, and optimizing how interventions are delivered.
2) What is the main goal of this funding opportunity?
The central goal is to support R01 projects that can determine whether behavioral and integrative interventions work (efficacy), explain how and why they work (mechanisms of behavior change), and identify the best delivery strategies (such as dose, combinations, and sequencing) that are practical and improve outcomes.
3) What kinds of research does NIH emphasize in this FOA?
The FOA emphasizes later-stage intervention research, including Stage II and Stage III efficacy work. This generally means studies that go beyond feasibility or pilot testing and instead use stronger designs, clearer outcomes, and more robust clinical trial methods when appropriate.
4) Is this FOA only for creating brand-new interventions?
No. A major theme is optimization. The FOA supports not only the creation of new interventions, but also improving existing approaches by identifying the most effective components, the right intensity or dose, and practical ways to combine behavioral strategies with medications to produce better outcomes.
5) What does "integrative treatment" mean in the context of this FOA?
Based on the description, integrative treatment includes approaches that combine behavioral interventions with pharmacological (medication) treatments, including studying how to best combine and sequence these components to improve substance use and related health outcomes.
6) What are the major research areas encouraged by the FOA?
The FOA highlights six broad areas: (1) drug abuse treatment interventions, including integrated behavioral and pharmacological approaches, across diverse real-world settings and including patients with comorbidities; (2) treatment and adherence interventions usable in primary care; (3) technology-enhanced interventions to strengthen effects and expand reach; (4) interventions to prevent HIV acquisition or transmission among individuals in drug abuse treatment; (5) interventions to improve adherence to drug abuse treatment and to HIV and addiction medications; and (6) behavioral interventions relevant to chronic pain treatment.
7) Are comorbidities and complex patient populations within scope?
Yes. The FOA explicitly prioritizes interventions that can be applied in diverse real-world settings and that address patients with comorbidities, such as co-occurring mental health conditions or other medical problems.
8) Does the FOA support work in primary care settings?
Yes. It promotes development and testing of drug abuse treatment and adherence interventions that can be used in primary care, reflecting the increasing role of general medical settings in identifying and managing substance use disorders.
9) What kinds of technology-enhanced interventions are included?
The FOA includes technology-enhanced interventions that use digital tools to strengthen treatment effects, expand reach, reduce burden on clinics, and improve the likelihood that interventions can be implemented consistently outside of research settings.
10) Does this FOA include HIV-related interventions?
Yes. It explicitly includes interventions aimed at preventing HIV acquisition or transmission among individuals who are in drug abuse treatment, recognizing the overlap between substance use, risk behavior, and HIV outcomes.
11) Is adherence research part of this opportunity?
Yes. The FOA supports interventions that improve adherence both to drug abuse treatment and to HIV and addiction medications, noting that adherence can be the practical barrier between evidence-based treatment and real benefit.
12) How does chronic pain fit into this FOA?
The FOA includes behavioral interventions relevant to chronic pain treatment, describing chronic pain as intersecting with addiction risk and medication use and noting it as a significant public health concern.
13) What types of study designs does the FOA encourage?
Supported work can include clinical trials to establish efficacy, studies that investigate mechanisms of behavior change (such as cognitive, social, or environmental processes that mediate outcomes), dose-response research to determine needed intensity or frequency, and studies comparing sequences or combinations of behavioral and medication treatments.
14) What is meant by mechanisms of behavior change in this FOA?
The FOA refers to identifying the processes that explain why an intervention works, such as cognitive, social, or environmental mechanisms that mediate clinical or behavioral outcomes.
15) What does "dose" mean for behavioral interventions?
In this FOA, dose refers to the intensity, frequency, or amount of the intervention needed to produce benefit, and the opportunity supports dose-response research to determine what level is most effective and practical.
16) Does the FOA support testing combinations or sequences of treatments?
Yes. It encourages research testing whether certain combinations or sequences (including sequential strategies that start with one approach and step up to another) and integrated behavioral plus medication approaches outperform alternatives.
17) Are integrated care models within scope?
Yes. The FOA encourages research on integrated care models, including combined interventions aiming to improve substance use outcomes and related health risks.
18) What grant mechanism is used, and what does that imply?
This opportunity uses the NIH R01 mechanism, which is intended for substantial, hypothesis-driven research projects with enough scope to conduct rigorous intervention testing and refinement.
19) Is cost sharing or matching required?
No. The announcement indicates there is no cost sharing or matching requirement.
20) Who is eligible to apply?
Eligibility is broad. Eligible applicants include many domestic and international organizations, including government entities (state, county, city/township, special districts), public housing and Indian housing authorities, public and private higher education institutions, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses), independent school districts, and Native American tribal governments and organizations (federally recognized and other than federally recognized).
21) Are historically underserved-serving or mission-driven institutions included in eligibility?
Yes. The eligibility language explicitly includes entities such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and federal government agencies.
22) Are foreign organizations eligible?
Yes. Foreign organizations and foreign institutions are eligible, non-U.S. components of U.S. organizations may apply, and foreign components are allowed as defined by the NIH Grants Policy Statement.
23) What are the key dates for this FOA?
The opportunity was posted on January 9, 2013, created on February 14, 2013, had an original and final closing date of January 7, 2016, and an archive date of February 7, 2016.
24) Is this funding opportunity still open?
No. Based on the provided dates, it is archived and the final closing date has passed.
25) Where can applicants find the official announcement information?
The official NIH Grants Guide announcement link provided is: http://grants.nih.gov/grants/guide/pa-files/PA-13-077.html
26) Who was listed as a contact for technical access or linking issues?
Technical access or linking issues were directed to the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: Behavioral Integrative Treatment Development Program (R03)
Previous opportunity: Behavioral Integrative Treatment Development Program (R34)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 077
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 077) also looked into and applied for these:
| Funding Opportunity |
|---|
| Behavioral Integrative Treatment Development Program (R03) Apply for PA 13 079 Funding Number: PA 13 079 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01) Apply for PAR 13 080 Funding Number: PAR 13 080 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Bridging the Gap Between Cancer Mechanism and Population Science (U01) Apply for PAR 13 081 Funding Number: PAR 13 081 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25) Apply for PAR 13 084 Funding Number: PAR 13 084 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) Apply for PAR 13 086 Funding Number: PAR 13 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (UM1) Apply for PAR 13 087 Funding Number: PAR 13 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Planning for a National Center for Particle Beam Radiation Therapy Research (P20) Apply for PAR 13 096 Funding Number: PAR 13 096 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI Experimental Therapeutics Clinical Trials Network with Phase 1 Emphasis (ET CTN) (UM1) Apply for RFA CA 13 006 Funding Number: RFA CA 13 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $850,000 |
| The Influence of the Microbiome on Preterm Labor and Delivery (R01) Apply for RFA NR 13 002 Funding Number: RFA NR 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| The Influence of the Microbiome on Preterm Labor and Delivery (R21) Apply for RFA NR 13 003 Funding Number: RFA NR 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Collaborative Human Tissue Network (CHTN) (UM1) Apply for RFA CA 13 007 Funding Number: RFA CA 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,200,000 |
| Research on Marijuana Legalization in the US (Admin Supp) Apply for PA 13 138 Funding Number: PA 13 138 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Lasker Clinical Research Scholars Program (Si2) Apply for RFA OD 13 004 Funding Number: RFA OD 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Multicenter AIDS Cohort Study Center for the Coordination, Analysis, and Management of the MACS (CAMACS)(UM1) Apply for RFA AI 13 010 Funding Number: RFA AI 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,400,000 |
| Limited Competition Multicenter AIDS Cohort Study (MACS) Clinical Research Sites (U01) Apply for RFA AI 13 011 Funding Number: RFA AI 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $4,200,000 |
| Limited Competition Scholars Training for the Advancement of Research (STAR) Revision to NINR T32 Training Grants (T32) Apply for RFA NR 13 010 Funding Number: RFA NR 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) Apply for PAR 13 146 Funding Number: PAR 13 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 14 003 Funding Number: RFA DA 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 13 157 Funding Number: PA 13 157 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33) Apply for PAR 13 158 Funding Number: PAR 13 158 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 077", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.